Core Viewpoint - A class action securities lawsuit has been filed against RxSight, Inc. alleging securities fraud that negatively impacted investors between November 7, 2024, and July 8, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that RxSight, Inc. faced "adoption challenges" and structural issues leading to declines in sales and utilization [2]. - It is alleged that the defendants overstated the demand for RxSight's products [2]. - The company is said to be unlikely to meet its previously issued financial guidance for fiscal year 2025 due to these issues [2]. - Positive statements made by the defendants regarding the company's business and prospects are claimed to be materially misleading and lacking a reasonable basis [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until September 22, 2025, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - A class action securities lawsuit has been filed against Altimmune, Inc. due to alleged securities fraud affecting investors between August 10, 2023, and June 25, 2025 [1] Group 1: Lawsuit Details - The lawsuit follows a press release from Altimmune on June 26, 2025, announcing disappointing results from the IMPACT Phase 2b MASH trial of Pemvidutide, where the company failed to achieve statistical significance in the primary endpoint of fibrosis reduction [2] - The stock price of Altimmune plummeted by 53.2%, from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, following the announcement of the trial results [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until October 6, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to serving clients [4]

Core Viewpoint - A class action securities lawsuit has been filed against Flywire Corporation, alleging securities fraud that affected investors between February 28, 2024, and February 25, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that Flywire's revenue growth was overstated, and the negative impact of permit and visa-related restrictions on its business was understated [2]. - Defendants' public statements regarding Flywire were allegedly materially false and misleading throughout the relevant period [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until September 23, 2025, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3]. Group 3: Law Firm Background - Levi & Korsinsky has a history of securing significant compensation for shareholders and has been recognized as one of the top securities litigation firms in the U.S. for seven consecutive years [4].

Core Viewpoint - A class action securities lawsuit has been filed against Charter Communications, Inc. alleging securities fraud that adversely affected investors during a specific time frame [1][2]. Class Definition - The lawsuit represents all individuals and entities who purchased or acquired Charter securities, including call options and put options, between July 26, 2024, and July 24, 2025 [2]. Case Details - The complaint alleges that Charter Communications made false statements and concealed significant issues, including: - The end of the Affordable Connectivity Program (ACP) was a material event that the Company could not manage effectively [3]. - The ACP's conclusion had a sustained negative impact on Internet customer declines and revenue [3]. - The Company failed to execute broader operations to compensate for the impact of the ACP ending [3]. - The decline in Internet customers and the failure of Charter's execution strategy posed greater risks to business plans and earnings growth than reported [3]. - The Company lacked a reasonable basis for its positive statements regarding operations and long-term growth [3]. Next Steps - Investors who suffered losses during the relevant time frame have until October 14, 2025, to request appointment as lead plaintiff, although participation does not require serving in this role [4]. Why Levi & Korsinsky - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions for shareholders and being recognized as one of the top securities litigation firms in the U.S. for seven consecutive years [5].

NEW YORK, Aug. 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in RxSight, Inc. ("RxSight, Inc." or the "Company") (NASDAQ: RXST) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of RxSight, Inc. investors who were adversely affected by alleged securities fraud between November 7, 2024 and July 8, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/rxsight-inc-lawsuit-submis ...

NEW YORK, Aug. 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Petco Health and Wellness Company, Inc. ("Petco" or the "Company") (NASDAQ: WOOF) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Petco investors who were adversely affected by alleged securities fraud between January 14, 2021 and June 5, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/petco-lawsuit-su ...

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock price following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Central District of California, titled Makaveev v. RxSight, Inc., et al., No. 25-cv-01596, with investors having until September 22, 2025, to seek lead plaintiff status [2]. Group 3: Financial Performance and Stock Impact - RxSight experienced a significant stock price decline after announcing a revenue forecast cut on April 3, 2025, with shares dropping approximately 38% from $26.12 to $16.21 [5]. - A further revenue forecast reduction on July 8, 2025, led to another 38% decline in stock price, from $12.79 to $7.95, attributed to slower LAL utilization and adoption challenges [6].

Core Viewpoint - Investors in SelectQuote, Inc. have the opportunity to lead a securities fraud class action lawsuit due to alleged misconduct by the company [1][2]. Summary by Relevant Sections Lawsuit Details - The lawsuit alleges that from September 9, 2020, to May 1, 2025, SelectQuote failed to disclose critical information to investors, including: - The company directed Medicare beneficiaries to insurers that compensated SelectQuote the most, regardless of plan quality [2]. - SelectQuote did not provide unbiased comparisons for Medicare Advantage insurance plans [2]. - The company received illegal kickbacks to steer beneficiaries to certain insurers while limiting enrollment in competitors' plans [2]. - SelectQuote's actions resulted in non-compliance with laws, regulations, and contractual obligations [2]. - The company was at risk of regulatory and legal sanctions, including potential violations of the False Claims Act [2]. - Positive statements made by the defendants regarding the company's business and prospects were materially misleading [2]. Participation Information - Investors who suffered losses in SelectQuote are encouraged to participate in the ongoing lawsuit before the lead plaintiff deadline of October 10, 2025 [2]. - Interested parties can contact the Law Offices of Frank R. Cruz for more information [3][4].

Core Viewpoint - A class action securities lawsuit has been filed against Flywire Corporation, alleging securities fraud that affected investors between February 28, 2024, and February 25, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that Flywire's revenue growth was overstated, and the negative impact of permit and visa-related restrictions on its business was understated, leading to materially false and misleading public statements [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until September 23, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Law Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A class action securities lawsuit has been filed against Novo Nordisk A/S, alleging securities fraud that negatively impacted investors between May 7, 2025, and July 28, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Novo Nordisk made misleading statements about its growth potential, particularly regarding the compounded GLP-1 market and the likelihood of patients switching to its branded products [2]. - On July 29, 2025, Novo Nordisk lowered its sales and profit outlook for the second half of 2025, attributing this to lower growth expectations for its products Wegovy and Ozempic, compounded GLP-1 usage, and increased competition [2]. - Following the announcement, Novo's stock price dropped from $69.00 per share on July 28, 2025, to $53.94 per share on July 29, 2025, marking a decline of approximately 21.83% in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 30, 2025, to request to be appointed as lead plaintiff in the lawsuit [3]. - Participation in the lawsuit does not require any out-of-pocket costs or fees for class members [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].